文献速递细胞病理与分子病理

细胞学样本中p53表达或为早期癌症标志物

p53 expression in cytology samples may represent a marker of early-stage cancer.
PubMed 文献 · Cancer Cytopathol · 2023-03-27

该前瞻性研究对162例甲状腺细胞学及对应组织学样本(从意义不明的异型性到恶性)行p53免疫细胞化学,并以50例良性病变为阴性对照。结果显示p53阳性与较大结节、高细胞亚型、多灶性、甲状腺外浸润及淋巴结转移相关;100%的AUS和86.5%的FN病例p53阴性且均无恶性组织学。p53可能有助于鉴别甲状腺滤泡性病变及识别低分化甲状腺癌中的不确定病变。

要点

  • p53阳性与较大结节、高细胞亚型、多灶性、甲状腺外浸润及淋巴结转移相关。
  • 100%的AUS和86.5%的FN病例p53阴性,且均无恶性组织学。
  • p53可能有助于鉴别甲状腺滤泡性病变及识别不确定病变中的高分化甲状腺癌。

核心结论

  • p53可能有助于鉴别甲状腺滤泡性病变。
  • p53可能是识别不确定病变中高分化甲状腺癌的有用诊断标志物。

研究设计与样本

  • 前瞻性研究纳入162例甲状腺细胞学及对应组织学样本,诊断从AUS到恶性。
  • 另用50例良性病变作为阴性对照。
  • 采用免疫细胞化学检测p53,仅对p53进行分子分析。

主要发现

  • 细胞学诊断分布为50例良性、48例AUS、40例滤泡性肿瘤、23例可疑恶性、1例恶性。
  • p53阴性102例,阳性60例;阳性中27例为弱和/或局灶胞质阳性(+1),33例为中(2+)至强(3+)胞质和/或核表达。
  • 71例有组织学结果(2例良性、11例AUS、37例滤泡性肿瘤、20例可疑恶性、1例恶性),其中61.7%为良性诊断、38.2%为恶性诊断。
  • 71例中仅16例(5例滤泡性肿瘤、10例可疑恶性、1例恶性)p53阳性。
  • 所有p53阳性病例均与较大结节尺寸、高细胞亚型、多灶性、甲状腺外浸润和淋巴结转移相关。

临床怎么用

  • 在甲状腺细胞学不确定病变中可考虑检测p53,辅助识别高分化甲状腺癌。
  • p53阳性结果应结合结节大小、高细胞亚型、多灶性、甲状腺外浸润及淋巴结转移等特征综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TP53 gene plays a major role in the negative control of cell proliferation and in the regulation of signaling cascades. TP53 mutation may have a relevant role in the malignant transformation of thyroid cells as well as thyroid tumor progression. TP53 mutation has been detected only in few well differentiated thyroid carcinomas and is absent in benign conditions. METHODS: A total of 162 prospective thyroid cytology and corresponding histological samples diagnosed from atypia of indeterminate significance (AUS) to malignant, were studied via immunocytochemistry for p53. Hence, 50 benign lesions (B) were used as negative control. Molecular analysis for p53 only was performed. RESULTS: The cytology resulted in 50 B, 48 AUS, 40 follicular neoplasms (FNs), 23 suspicious for malignancy (SFM), and 1 malignant (M) case. The authors reported 102 negative and 60 positive p53 cases. The 60 positive cases included 27 cases with weak and/or focal cytoplasmic positivity (+1) and 33 with cases moderate (2+) to strong (3+) cytoplasmic and/or nuclear expression. Overall, 71 cases had histology (2 B, 11 AUS, 37 FN, 20 SFM, and 1 M) including 61.7% benign and 38.2% malignant diagnoses. Only 16 of 71 (5 FN, 10 SFM, and 1 M) were p53-positive. Furthermore, 100% AUS and 86.5% FN cases were p53-negative, none of which had malignant histology. All p53-positive cases were associated with a larger nodule size, tall-cell variant subtype, multifocality, extra thyroidal infiltration, and nodal metastases. Noninvasive follicular thyroid neoplasm with papillary like nuclear features were negative for p53. Few discrepancies in p53 intensity were observed on histology; there were no differences with the molecular testing. CONCLUSIONS: p53 might be useful in discriminating thyroid follicular lesions. p53 is likely to be a useful diagnostic marker in recognizing indeterminate lesions that are well-differentiated thyroid cancers.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Policardo F, Tralongo P, Arciuolo D, et al. p53 expression in cytology samples may represent a marker of early-stage cancer. Cancer Cytopathol. 2023. PMID: 36974003. doi:10.1002/cncy.22694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。